# A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

> **NCT01972776** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** QBM076
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01972776
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Part 1 was completed. Part 2 was terminated for safety reasons.
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972776, "A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01972776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*